A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Entospletinib (ENTO) as Monotherapy in Japanese Subjects With Relapsed or Refractory Hematologic Malignancies and in Combination With Chemotherapy in Japanese Subjects With Previously Untreated Acute Myeloid Leukemia (AML)
Latest Information Update: 09 Mar 2020
At a glance
- Drugs Entospletinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Haematological malignancies
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 14 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 19 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 01 Oct 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.